OSE Immunotherapeutics to Present Data on Lusvertikimab at DDW 2025

OSE Immunotherapeutics will present new findings from the Phase 2 extension of their CoTikiS trial at the Digestive Disease Week conference in San Diego, focusing on Lusvertikimab for ulcerative colitis. The Open Label Extension (OLE) study spans 24 weeks and evaluates the long-term benefits and safety of this anti-IL-7 receptor monoclonal antibody.

Previously, the induction period results were highlighted at the 2025 ECCO congress. The new data promises deeper insights into Lusvertikimab's potential, not only for ulcerative colitis but also other autoimmune diseases.

The conference session, "Lusvertikimab, a First in Class IL7 Receptor Antagonist, in Moderate to Severe Ulcerative Colitis," will take place on May 5, 2025. Lusvertikimab continues to be a promising candidate amidst high remission challenges in ulcerative colitis.